You are viewing: China Minimal Residual Disease Market analysis

The China Minimal Residual Disease Market was valued at $86.9 Million in 2024 and projected to reach to $168.6 Million by 2029, representing a compound annual growth rate of 14.2%. China's Minimal Residual Disease market is positioned for sustained growth through 2029, driven by increasing healthcare expenditure and modernization of diagnostic infrastructure.

China Minimal Residual Disease Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Minimal Residual Disease Market Trends and Insights

  • This represents a compound annual growth rate of 14.2%, significantly outpacing global trends.
  • China's rapid adoption of advanced diagnostic technologies, coupled with increasing investments in oncology and hematology research, is driving market penetration across major urban centers and emerging healthcare hubs. The growth trajectory in China reflects rising cancer incidence, enhanced healthcare infrastructure, and government initiatives supporting precision medicine adoption.
  • China's healthcare system is increasingly integrating MRD testing into treatment protocols for hematologic malignancies and solid tumors.
  • Between 2024 and 2029, China is expected to capture substantial market share within the Asia Pacific region, driven by expanding clinical laboratory networks and growing awareness among oncologists regarding MRD's prognostic value. China's competitive landscape features both international diagnostic companies and emerging domestic players establishing manufacturing and distribution capabilities.
  • The market's acceleration underscores China's commitment to modernizing cancer care standards and aligning with international best practices in minimal residual disease monitoring..

Key Market Statistics

  • CAGR (2024-2029) 14.2% CAGR
  • Market Size, 2024 ~USD 86.9 Million
  • Forecast, 2029 ~USD 168.6 Million
  • Country China

China Minimal Residual Disease Market Overview

Rapid Market Expansion :

China's MRD market is growing at 14.2% CAGR, significantly outpacing the global rate of 12.2%, driven by increasing healthcare investments and oncology focus.

Advanced Diagnostic Adoption :

Chinese healthcare institutions are rapidly adopting next-generation sequencing and flow cytometry technologies for MRD detection in leukemia and lymphoma patients.

Government Support & Research Investment :

Substantial government funding for cancer research and precision medicine initiatives is accelerating MRD test development and clinical implementation across Chinese hospitals.

Growing Patient Population :

Rising incidence of hematologic malignancies in China, combined with improved early detection programs, is expanding the addressable patient base for MRD testing.

China Minimal Residual Disease Market Dynamics

  • The country's emphasis on precision oncology and government-backed cancer control initiatives are creating favorable conditions for MRD technology adoption.
  • Major Chinese hospitals and research institutions are integrating MRD testing into standard treatment protocols, particularly for acute leukemia and multiple myeloma management.
  • Expanding reimbursement coverage and growing awareness among clinicians will further accelerate market penetration.
  • By 2029, China is expected to become a significant contributor to global MRD market growth, with emerging domestic manufacturers complementing established international players..

Related Ecosystem

Analytical And Scientific Instrumentation

Top Technologies
  • Environmental Testing
  • Gas Chromatography
  • Polymerase Chain Reaction (PCR)
  • Automated Liquid Handling Systems
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Shimadzu Corporation
  • Merck KGaA

    Diagnostic Imaging

    Top Technologies
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • CT Scanners
    • Nuclear Imaging
    • Positron Emission Tomography
    Top Companies
    • Siemens healthineers
    • PHILIPS HEALTHCARE
    • CANON INC.
    • FUJIFILM Holdings Corporation
    • UNITED IMAGING HEALTHCARE CO., LTD.

      In Vitro Diagnostics

      Top Technologies
      • Polymerase Chain Reaction (PCR)
      • Enzyme-Linked Immunosorbent Assay (ELISA)
      • Dna Microarrays
      • Assay Kits
      • Microarrays
      Top Companies
      • ROCHE HOLDINGS AG
      • Thermo Fisher Scientific Inc.
      • Danaher Corporation
      • Abbott Laboratories
      • Biomerieux s.a.

        Key Takeaways

        • China's MRD market is valued at $86.9 million in 2024 and is forecast to nearly double to $168.6 million by 2029, reflecting a 14.2% CAGR.
        • China's healthcare modernization and precision medicine initiatives are accelerating MRD test adoption across oncology and hematology departments.
        • China's market growth outpaces the global average, positioning the country as a key growth engine within the Asia Pacific region.
        • China's competitive environment includes both multinational diagnostics firms and domestic innovators expanding MRD testing capabilities and accessibility.

        Minimal Residual Disease Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment MULTIPLE MYELOMA (Application)
        Forecast Period 2024-2029
        Growth Rate CAGR of 12.2% from 2024 to 2029
        Largest Segment ASSAY KITS & REAGENTS (Product)
        Market Size Base Year (Billions) ~USD 1.43 (2024)
        Revenue Forecast (Billions) ~USD 2.55 (2029)
        Segments Covered Product, Technology, Application, Type, End User

        China Minimal Residual Disease Market Report Segmentation

        5 segment dimensions are covered across the global market.

        By Product

        • Assay Kits & Reagents
        • Instruments

        By Technology

        • Flow Cytometry
        • Next-Generation Sequencing
        • Other Technologies
        • Polymerase Chain Reaction

        By Application

        • Hematological Malignancies
        • Multiple Myeloma
        • Other Applications
        • Solid Tumors

        By Type

        • Hodgkin Lymphoma
        • Leukemia
        • Lymphoblastic Leukemia
        • Lymphocytic Leukemia
        • Lymphoma
        • Myeloid Leukemia
        • Non-Hodgkin Lymphoma
        • Other Leukemias

        By End User

        • Academic & Research Institutes
        • Diagnostic Laboratories
        • Hospitals & Specialty Clinics
        • Other End Users

        CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029

        Segment20222023202420252026202720282029CAGR (%)
        ACADEMIC & RESEARCH INSTITUTES14.516.819.322.125.228.832.737.114
        DIAGNOSTIC LABORATORIES30.836.14248.956.765.675.787.215.7
        HOSPITALS & SPECIALTY CLINICS44.35158.667.176.787.399.2112.413.9
        OTHER END USERS7.8910.41213.815.81820.614.6
        TOTAL97.4112.9130.3150.1172.4197.5225.6257.314.6

        Target Audience

        • In Vitro Diagnostics Manufacturers : IVD companies need China-specific market data to develop localized MRD testing solutions, navigate regulatory requirements, and identify partnership opportunities with Chinese healthcare providers.
        • Pharmaceutical & Biotech Companies : Oncology and hematology firms require MRD market insights to support companion diagnostic development, clinical trial design, and market launch strategies in China's growing cancer treatment sector.
        • Healthcare Investment Firms : Private equity and venture capital investors need validated market sizing and growth projections for China's MRD sector to evaluate investment opportunities and portfolio company valuations.
        • Hospital & Laboratory Networks : Chinese hospital systems and diagnostic laboratories need competitive benchmarking and technology adoption data to optimize MRD testing capabilities and clinical protocols.
        • Healthcare Consultants & Advisors : Strategy consultants supporting clients in China's healthcare sector require detailed market analysis to inform business development, market entry, and competitive positioning recommendations.

        Reasons to Buy this Report

        • Market Size & Growth Validation : Obtain precise valuation data for China's MRD market ($86.9M in 2024) with verified 14.2% CAGR projections through 2029 to support investment and expansion decisions.
        • Competitive Landscape Intelligence : Identify key players, emerging domestic manufacturers, and market share distribution specific to China's MRD sector to benchmark competitive positioning.
        • Regulatory & Reimbursement Insights : Understand China-specific regulatory pathways, government reimbursement policies, and healthcare system dynamics affecting MRD test adoption and market access.
        • Technology Adoption Trends : Analyze which MRD technologies (NGS, flow cytometry, digital PCR) are gaining traction in Chinese hospitals and research institutions for strategic product development.
        • Growth Driver Analysis : Leverage detailed insights on government funding, cancer incidence trends, and clinical adoption patterns to identify high-potential market segments and entry opportunities in China.

        Frequently asked questions

        What is the current market size of MRD testing in China?

        China's Minimal Residual Disease market was valued at $86.9 million in 2024 and is expected to grow to $168.6 million by 2029.

        What is the projected growth rate for China's MRD market?

        China's MRD market is projected to grow at a compound annual growth rate (CAGR) of 14.2% from 2024 to 2029.

        What factors are driving MRD market growth in China?

        Key drivers include rising cancer incidence, government support for precision medicine, expanding healthcare infrastructure, and increasing adoption of advanced diagnostic technologies in China's clinical laboratories.

        How does China's MRD market growth compare to global trends?

        China's 14.2% CAGR significantly exceeds the global average of 12.2%, making China one of the fastest-growing markets for MRD testing worldwide.

        Which therapeutic areas are driving MRD adoption in China?

        Hematologic malignancies and solid tumors are the primary therapeutic areas driving MRD test adoption in China's oncology and hematology treatment protocols.

        RESEARCH METHODOLOGY

        This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

        Secondary Research

        In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

        Primary Research

        In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

        The following is a breakdown of the primary respondents:

        Minimal Residual Disease Market

        Note 1: Others include sales managers, marketing managers, and product managers.

        Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

        To know about the assumptions considered for the study, download the pdf brochure

        COMPANY NAME DESIGNATION
        Roche Ltd. General Manager
        Gaurdant Area Sales Manager

        Market Size Estimation

        Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

        • The key players in the industry have been identified through extensive secondary research
        • The revenues generated by leading players operating in the minimal residual disease testing market have been determined through primary and secondary research
        • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

        The research methodology used to estimate the market size includes the following:

        Minimal Residual Disease Market

        Data Triangulation

        After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

        Market Definition

        Minimal Residual Disease (MRD) refers to the small number of cancer cells left in a body after cancer treatment. MRD tests are performed to diagnose and monitor patients with various hematology cancers, such as leukemia, lymphoma, and myeloma. An MRD test looks for cancer cells not killed by chemotherapy or other cancer treatments. Moreover, these tests also play a crucial role in clinical trials of hemato-oncology therapeutics.

        Stakeholders

        • Senior Management
        • End User
        • Finance/Procurement Department 
        • R&D Department

        Report Objectives

        • To define, describe, segment, and forecast the global minimal residual disease testing market by product, technology, application, end user, and region
        • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
        • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
        • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
        • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
        • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market
        • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

         

        Get the Full Minimal Residual Disease Market Report

        Full forecast, segment splits, and company analysis for all Minimal Residual Disease Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status